Literature DB >> 2144364

Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

L Raycroft1, H Y Wu, G Lozano.   

Abstract

The protein encoded by the wild-type p53 proto-oncogene has been shown to suppress transformation, whereas certain mutations that alter p53 become transformation competent. Fusion proteins between p53 and the GAL4 DNA binding domain were made to anchor p53 to a DNA target sequence and to allow measurement of transcriptional activation of a reporter plasmid. The wild-type p53 stimulated transcription in this assay, but two transforming mutations in p53 were unable to act as transcriptional activators. Therefore, p53 can activate transcription, and transformation-activating mutations result in a loss of function of the p53 protein. The inability of the p53 mutant proteins to activate transcription may enable them to be transformation competent.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144364      PMCID: PMC2935288          DOI: 10.1126/science.2144364

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  33 in total

1.  Transcription activation by the adenovirus E1a protein.

Authors:  J W Lillie; M R Green
Journal:  Nature       Date:  1989-03-02       Impact factor: 49.962

2.  Rearrangement of the p53 gene in human osteogenic sarcomas.

Authors:  H Masuda; C Miller; H P Koeffler; H Battifora; M J Cline
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  Separation of DNA binding from the transcription-activating function of a eukaryotic regulatory protein.

Authors:  L Keegan; G Gill; M Ptashne
Journal:  Science       Date:  1986-02-14       Impact factor: 47.728

4.  Growth regulation of a cellular tumour antigen, p53, in nontransformed cells.

Authors:  N C Reich; A J Levine
Journal:  Nature       Date:  1984 Mar 8-14       Impact factor: 49.962

5.  Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny.

Authors:  M Oren; N C Reich; A J Levine
Journal:  Mol Cell Biol       Date:  1982-04       Impact factor: 4.272

6.  Characterization of enhancer elements in the long terminal repeat of Moloney murine sarcoma virus.

Authors:  L A Laimins; P Gruss; R Pozzatti; G Khoury
Journal:  J Virol       Date:  1984-01       Impact factor: 5.103

7.  Wild-type p53 can inhibit oncogene-mediated focus formation.

Authors:  D Eliyahu; D Michalovitz; S Eliyahu; O Pinhasi-Kimhi; M Oren
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

8.  Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins.

Authors:  C V Dang; W M Lee
Journal:  J Biol Chem       Date:  1989-10-25       Impact factor: 5.157

9.  Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53.

Authors:  T Soussi; C Caron de Fromentel; M Méchali; P May; M Kress
Journal:  Oncogene       Date:  1987-03       Impact factor: 9.867

10.  Common DNA binding site for Fos protein complexes and transcription factor AP-1.

Authors:  F J Rauscher; L C Sambucetti; T Curran; R J Distel; B M Spiegelman
Journal:  Cell       Date:  1988-02-12       Impact factor: 41.582

View more
  184 in total

1.  Identification and classification of p53-regulated genes.

Authors:  J Yu; L Zhang; P M Hwang; C Rago; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

2.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays.

Authors:  R Zhao; K Gish; M Murphy; Y Yin; D Notterman; W H Hoffman; E Tom; D H Mack; A J Levine
Journal:  Genes Dev       Date:  2000-04-15       Impact factor: 11.361

3.  Relationship of p53 mutations to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis.

Authors:  J G Einspahr; D S Alberts; J A Warneke; P Bozzo; J Basye; T M Grogan; M A Nelson; G T Bowden
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

4.  Partial purification and characterization of an 80-kDa transcription factor binding to bHLH motif in the rat p53 promoter.

Authors:  Minhyung Lee; Yong-beom Lim; Jong-sang Park
Journal:  Mol Biol Rep       Date:  2002-12       Impact factor: 2.316

Review 5.  Molecular genetics of neurological tumours.

Authors:  R Y Chung; B R Seizinger
Journal:  J Med Genet       Date:  1992-06       Impact factor: 6.318

6.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.

Authors:  E Shaulian; A Zauberman; D Ginsberg; M Oren
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

7.  Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53.

Authors:  D M Milne; R H Palmer; D W Meek
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

Review 8.  Cancer risks from germline p53 mutations.

Authors:  T Frebourg; S H Friend
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 9.  TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.

Authors:  Ashkan Shahbandi; Hoang D Nguyen; James G Jackson
Journal:  Trends Cancer       Date:  2020-02-05

10.  Mouse p53 represses the rat brain creatine kinase gene but activates the rat muscle creatine kinase gene.

Authors:  J Zhao; F I Schmieg; D T Simmons; G R Molloy
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.